On this page
Back to topMedline MDLN
Medline listed on Nasdaq on 18 Dec 2025 and is not in the S&P 500. It is worth $49.8 billion. Its price history starts on 19 Dec 2025. Its board has 12 directors, 9 of them independent. 8 other officers are on file. At 30 Jun 2026, Carlyle Group was its largest institutional holder, with 14.2% of the company.
- CEO
- James M. Boyle
- Chair
- Charles N. Mills
- Listed
- 18 Dec 2025 on Nasdaq, IPO filings and terms
- Headquarters
- Northfield, IL
- Market cap
- $49.8B
- 19 Nov 2026 close
- Price to sales
- 1.8
- Market cap over revenue
Financials
Financial history
Twelve months to 26 Sep 2026, from Medline's quarterly filings.
Quarters since Mar 2025
- Revenue
- $30.7B
- Last four quarters
- Net income
- $582M
- 1.9% of revenue
- Free cash flow
- $1.9B
- Operating cash flow less capital spending
- P/E
- 85.5
- Market cap over net income
Quarterly results
Each quarter's revenue, net income and free cash flow.
Mar 2025 to Sep 2026
| Quarter | Revenue | Net income |
|---|---|---|
| Sep 2026 | $7.9B | $198M |
| Jun 2026 | $7.7B | $59M |
| Mar 2026 | $7.4B | $132M |
| Dec 2025 | $7.8B | $193M |
| Sep 2025 | $7.1B | $318M |
| Jun 2025 | $6.9B | $329M |
| Mar 2025 | $6.6B | $319M |
Revenue breakdown
Medline's $7.9B of revenue, as its quarterly report splits it. Parts that are not a business, such as sales between segments, can be negative.
Quarter to Sep 2026
| Split by | Part | Revenue |
|---|---|---|
| Segment | Supply Chain Solutions | $4.2B |
| Segment | Medline Brand | $3.6B |
| Region | United States | $7.3B |
| Region | International | $518M |
Medline's market cap since December 2025
Weekly, up to 13 Nov 2026
| Week ending | Market cap |
|---|---|
| 13 Nov 2026 | $51.9B |
| 26 Dec 2025 | $58.0B |
Download Medline's data as JSON, with the weekly market caps in billions of dollars from 19 Dec 2025.
Board and leadership
Board and officers
3 people here also hold roles at other S&P 500 companies.
Board from the proxy filed 23 Apr 2026; officers filed up to 30 Sep 2026
| Name | Title | Since | Independent | Committees | Age |
|---|---|---|---|---|---|
| Directors (12) | |||||
| Charles N. MillsChairNot independent 路 since 1985 路 Risk and ComplianceNon-Executive Former Chief Executive Officer, Medline | |||||
| James M. BoyleChief Executive OfficerNot independent 路 since 2023 | |||||
| Joseph BarattaDirectorIndependent 路 since 2021Global Head of Private Equity, BlackstoneAlso at Blackstone | |||||
| Jacob BestDirectorIndependent 路 since 2021 路 Compensation, Nominating and Corporate Governance, Risk and Compliance (chair)Partner, Hellman & Friedman | |||||
| Todd M. BluedornDirectorIndependent 路 since 2025 路 AuditFormer Chief Executive Officer, Lennox International Inc.Also at Texas InstrumentsOther boards: Samsara | |||||
| Richard A. GalantiDirectorIndependent 路 since 2025 路 AuditFormer Chief Financial Officer, Costco Wholesale CorporationOther boards: Affirm Holdings | |||||
| Patrick J. HealyDirectorIndependent 路 since 2025Chief Executive Officer, Hellman & Friedman | |||||
| Andrew J. MillsDirectorNot independent 路 since 1985Former President, Medline; Chief Executive Officer and General Partner, Council Ring Capital, LLC | |||||
| Robert R. SchmidtDirectorIndependent 路 since 2021 路 Compensation, Nominating and Corporate Governance (chair), Risk and CompliancePartner and Global Co-Head of Healthcare, Carlyle | |||||
| Anushka M. SunderDirectorIndependent 路 since 2021 路 Compensation (chair), Nominating and Corporate Governance, Risk and ComplianceSenior Managing Director and Head of Healthcare Private Equity North America, Blackstone | |||||
| Thomas W. SweetDirectorIndependent 路 since 2024 路 Audit (chair), Risk and ComplianceFormer Chief Financial Officer, Dell TechnologiesAlso at 3M and Trimble | |||||
| Stephen H. WiseDirectorIndependent 路 since 2021Partner and Co-Head of Americas Corporate Private Equity, Carlyle | |||||
| Officers (8) | |||||
| Michael B. DrazinChief Financial OfficerLast filed 17 Jun 2026 | |||||
| William J. AbramsExecutive Vice President, Supply Chain SolutionsLast filed 17 Jun 2026 | |||||
| Jessi L. CorcoranPrincipal Accounting OfficerLast filed 9 Jun 2026 | |||||
| Douglas P. GolwasChief Commercial OfficerLast filed 17 Jun 2026 | |||||
| Amanda H. LaabsChief Product OfficerLast filed 17 Jun 2026 | |||||
| Alexander M. LibermanChief Legal OfficerLast filed 17 Jun 2026 | |||||
| James M. PigottPresidentLast filed 17 Dec 2025 | |||||
| Christopher P. ShryockChief Human Resources OfficerLast filed 17 Jun 2026 | |||||
Owners and trading
Largest institutional holders
Each fund group's share of Medline. Where a company has several share classes, the share is of its total value.
13F filings for the quarter to 30 Jun 2026
Insider trades
Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.
Trades from 19 Nov 2025 to 19 Nov 2026
Directors and officers sold $3.7 million of stock in 1 sale and bought $150 million in 3 purchases in the 12 months to 19 Nov 2026.
| Date | Person | Value |
|---|---|---|
| 16 Jun 2026Sale | Douglas P. GolwasChief Commercial Officer | $3.7M |
| 5 Jun 2026Buy | Jessi L. CorcoranPrincipal Accounting Officer | $171K |
| 18 Dec 2025Buy | Andrew J. MillsDirector | $75M |
| 18 Dec 2025Buy | Charles N. MillsChair | $75M |
Timeline
Leadership changes, layoffs and insider sales
20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025
2 departures and 1 appointment of directors and officers and 1 large insider sale in the last two years.
Insider sales of $1 million or more, and the largest tenth of Medline's insider sales.
Events, newest first
- 13 Oct 2026 Joseph P. Baratta resignedBoard, effective 31 Dec 2026
- 7 Jul 2026 Stephen L. Miller retiredChief Operating Officer, effective 30 Aug 2026
- 16 Jun 2026 Douglas P. Golwas sold $3.7MChief Commercial Officer
- 16 Dec 2025 Todd M. Bluedorn appointedBoard of Directors
Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet and no earnings release figures from the last six months.